Linical Co's EBIT per Share for the
six
months ended in Mar. 2026 was 円-108.94.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円-132.54.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Linical Co's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Linical Co was 44.50% per year. The lowest was -96.40% per year. And the median was 10.25% per year.
TSE:2183's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Linical Co's EBIT for the
six
months ended in Mar. 2026 was 円-2,461 Mil.
Linical Co (TSE:2183) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Linical Co EBIT per Share Related Terms
Linical Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Linical Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-132.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a EBIT per Share of 円-132.54 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Linical Co and its competitors. According to the industry distribution chart, Linical Co ranks #999999 out of 1172 companies in the Biotechnology industry.
Is Linical Co's EBIT per Share too high?
Linical Co's current EBIT per Share is 円-132.54. Based on the distribution chart, Linical Co ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Linical Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #999999 out of 1172 companies for EBIT per Share. This places Linical Co in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current EBIT per Share is 円-132.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円316.17, compared to a current price of 円212.00 — trading 32.9% below its estimated fair value. The current EBIT per Share is 円-132.54. Linical Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Linical Co (TSE:2183), the current EBIT per Share is 円-132.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円212.00 is trading 32.9% below its estimated GF Value™ of 円316.17.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
EBIT per Share: 円-132.54
GF Value™: 円316.17 vs. price of 円212.00 (32.9% below fair value)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
